Safety of Combined Pirfenidone and Nintedanib in Subgroups of Patients with Idiopathic Pulmonary Fibrosis (IPF)

被引：0

作者：

Flaherty, K. ^{[1
]}

Fell, C. D. ^{[2
]}

Huggins, J. T. ^{[3
]}

Nunes, H. ^{[4
]}

Sussman, R. ^{[5
]}

Valenzuela, C. ^{[6
]}

Petzinger, U. ^{[7
]}

Stauffer, J. L. ^{[8
]}

Gilberg, F. ^{[9
]}

Bengus, M. ^{[9
]}

Wijsenbeek, M. ^{[10
]}

机构：

[1] Univ Michigan, Ann Arbor, MI 48109 USA

[2] Univ Calgary, Calgary, AB, Canada

[3] Med Univ South Carolina, Charleston, SC 29425 USA

[4] Hop Avicenne, Bobigny, France

[5] Atlantic Hlth Syst, Overlook Med Ctr, Summit, NJ USA

[6] Hosp Univ La Princesa, Inst Invest Princesa, Madrid, Spain

[7] Clinipace Accov GmbH, Eschborn, Germany

[8] Genentech Inc, San Francisco, CA 94080 USA

[9] F Hoffmann La Roche Ltd, Basel, Switzerland

[10] Erasmus Univ, Med Ctr, Rotterdam, Netherlands

来源：

关键词：

D O I：

暂无

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

A4252

引用

页数：2